Adenoiditis medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Adenoiditis}} {{CMG}}; {{AE}} {{MIR}} ==Overview== ==References== {{Reflist|2}}")
 
Line 4: Line 4:


==Overview==
==Overview==
== Medical Therapy ==
===Antimicrobial therapy===
*If the adenoiditis is caused by group A streptococus, then [[antibiotics]] are useful with [[penicillin]] or [[amoxicillin]] being first line.<ref name="pmid1459378">{{cite journal |author=Touw-Otten FW, Johansen KS |title=Diagnosis, antibiotic treatment and outcome of acute tonsillitis: report of a WHO Regional Office for Europe study in 17 European countries |journal=Fam Pract |volume=9 |issue=3 |pages=255–62 |year=1992 |pmid=1459378 |doi=10.1093/fampra/9.3.255}}</ref>
*Cephalosporins and [[macrolides]] are considered good alternatives to penicillin in the acute setting.<ref>Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 2004;113:866-882.</ref>
**A [[macrolide]] such as [[erythromycin]] is indicated for patients allergic to [[penicillin]].
*Individuals who fail penicillin therapy may respond to treatment effective against beta-lactamase producing bacteria.<ref>{{cite journal |author=Brook I |title=The role of beta-lactamase-producing-bacteria in mixed infections |journal=BMC Infect Dis |volume=9 |pages=202 |year=2009 |url=http://www.biomedcentral.com/1471-2334/9/202 |pmid=20003454 |pmc=2804585 |doi=10.1186/1471-2334-9-202}}</ref> such as [[clindamycin]] or [[amoxicillin-clavulanate]]. Aerobic and anaerobic beta lactamase producing bacteria that reside in the adenoidal tissues can "shield" group A streptococcus from penicillins.<ref>{{cite journal |author=Brook I |title=Microbiology and principles of antimicrobial therapy for head and neck infections |journal=Infect Dis Clin North Am |volume=21 |pages=355–91 |year=2007 |pmid=17561074 |url=http://linkinghub.elsevier.com/retrieve/pii/S0891-5520(07)00026-8 |doi=10.1016/j.idc.2007.03.014 |issue=2 }}</ref>
====Empiric Therapy====
*Preferred regimen: [[Penicillin V]] PO 10 days or if compliance unlikely, [[benzathine penicillin]] IM single dose<ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
*Alternate regimen (1): [[Cephalosporins|2nd generation Cephalosporins]] PO for 4–6 days
*Alternate regimen (2): [[Clindamycin]] or [[azithromycin]] for 5 days
*Alternate regimen (3): [[Clarithromycin]] for 10 days
*Alternate regimen (4): [[Erythromycin]] for 10 days
*Alternative regimen (5): [[Amoxicillin]] for 10 days
====Challenges of Treatment====
Despite in vitro efficacy, there is frequently reported inability of [[penicillin]] to fully resolve [[GABHS]] from patients with acute and relapsing adenoiditis.<ref name="pmid17292576">{{cite journal |vauthors=Casey JR, Pichichero ME |title=The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis |journal=Diagn. Microbiol. Infect. Dis. |volume=57 |issue=3 Suppl |pages=39S–45S |year=2007 |pmid=17292576 |doi=10.1016/j.diagmicrobio.2006.12.020 |url=}}</ref>
*Over the past 50 years, the rate of penicillin failure has consistently increased from about 7% in 1950 to almost 40% in 2000.
*There are several explanations for the failure of penicillin to eradicate [[GABHS]] adenoiditis:<ref name="pmid16251332">{{cite journal |vauthors=Brook I, Foote PA |title=Efficacy of penicillin versus cefdinir in eradication of group A streptococci and tonsillar flora |journal=Antimicrob. Agents Chemother. |volume=49 |issue=11 |pages=4787–8 |year=2005 |pmid=16251332 |pmc=1280135 |doi=10.1128/AAC.49.11.4787-4788.2005 |url=}}</ref>
**Poor penetration of [[penicillin]] into the adenoid tissues, as well as the epithelial cells.<ref name="cid.oxfordjournals.org">[http://cid.oxfordjournals.org/content/43/11/1398.full.pdf+html Kaplan EL, Chatwal GS, Rohde M.  Reduced ability of penicillin to eradicate ingested Group A streptococci from epithelial cells: clinical and pathogenetic implications. ''Clin Infect Dis''. 2006;43:1398-406.]</ref>
**Bacterial interactions between [[GABHS]] and the other members of the adenoidal bacterial flora.<ref name="pmid6390637">{{cite journal |vauthors=Brook I |title=The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection |journal=Rev. Infect. Dis. |volume=6 |issue=5 |pages=601–7 |year=1984 |pmid=6390637 |doi= |url=}}</ref>
***It is hypothesized that the enzyme [[beta-lactamase]], secreted by beta-lactamase-producing aerobic and anaerobic bacteria that colonize the [[pharynx]], [[tonsil]]s and adenoids, may “shield” [[GABHS]] from [[penicillin]].
****These organisms include ''S. aureus'', ''[[Haemophillus influenzae]]'', and ''[[Prevotella]]'', Porphyromonas and ''[[Fusobacterium]]'' spp.<ref name="pmid6968177">{{cite journal |vauthors=Brook I, Calhoun L, Yocum P |title=Beta-lactamase-producing isolates of Bacteroides species from children |journal=Antimicrob. Agents Chemother. |volume=18 |issue=1 |pages=164–6 |year=1980 |pmid=6968177 |pmc=283957 |doi= |url=}}</ref> A recent increase was noted in the recovery of MRSA which was isolated from 16% of adenoids, making it more difficult to eradicate this and other beta-lactamase producing organisms.<ref>Brook I, Foote PA. Isolation of methicillin resistant ''Staphylococcus aureus'' from the surface and core of tonsils in children. ''Int J Pediatr Otorhinolaryngol''. 2006 ;70:2099-102.</ref>
**Coaggregation between ''[[Moraxella catarrhalis]]'' and [[GABHS]], which can facilitate [[GABHS]] colonization.<ref name="pmid16849717">{{cite journal |vauthors=Brook I, Gober AE |title=Increased recovery of Moraxella catarrhalis and Haemophilus influenzae in association with group A beta-haemolytic streptococci in healthy children and those with pharyngo-tonsillitis |journal=J. Med. Microbiol. |volume=55 |issue=Pt 8 |pages=989–92 |year=2006 |pmid=16849717 |doi=10.1099/jmm.0.46325-0 |url=}}</ref>
**Absence of normal bacterial flora and resultant lack of interference on the growth of [[GABHS]], makeing it easier for [[GABHS]] to colonize and invade the adenoid area.<ref name="pmid6362282">{{cite journal |vauthors=Grahn E, Holm SE |title=Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area |journal=Zentralbl Bakteriol Mikrobiol Hyg A |volume=256 |issue=1 |pages=72–9 |year=1983 |pmid=6362282 |doi= |url=}}</ref><ref name="pmid7488371">{{cite journal |vauthors=Brook I, Gober AE |title=Role of bacterial interference and beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococcal pharyngotonsillitis |journal=Arch. Otolaryngol. Head Neck Surg. |volume=121 |issue=12 |pages=1405–9 |year=1995 |pmid=7488371 |doi= |url=}}</ref><ref name="pmid10326813">{{cite journal |vauthors=Brook I, Gober AE |title=Interference by aerobic and anaerobic bacteria in children with recurrent group A beta-hemolytic streptococcal tonsillitis |journal=Arch. Otolaryngol. Head Neck Surg. |volume=125 |issue=5 |pages=552–4 |year=1999 |pmid=10326813 |doi= |url=}}</ref>
**Poor penetration of penicillin into the adenoidal cells and adenoidal surface fluid (allowing intracellular survival of [[GABHS]])<ref name="cid.oxfordjournals.org" />
**Resistance (i.e., [[erythromycin]]) or tolerance (i.e., [[penicillin]]) to the administered antibiotic
**Inappropriate dose, duration of therapy, or choice of [[antibiotic]]
===Symptomatic Treatment and Pain Management===
*Treatments of adenoiditis consist of [[analgesics]] and [[lozenges]].<ref name="BoureauPelen1999">{{cite journal|last1=Boureau|first1=F|last2=Pelen|first2=F|last3=Verriere|first3=F|last4=Paliwoda|first4=A|last5=Manfredi|first5=R|last6=Farhan|first6=M|last7=Wall|first7=R|title=Evaluation of Ibuprofen vs Paracetamol Analgesic Activity Using a Sore Throat Pain Model|journal=Clinical Drug Investigation|volume=17|issue=1|year=1999|pages=1–8|issn=1173-2563|doi=10.2165/00044011-199917010-00001}}</ref>
**[[Analgesics]] can help reduce [[edema]] and [[inflammation]] to allow the patient to resume swallowing liquids.<ref name="BoureauPelen1999" />
*Topical anesthetics for temporary relief, such as viscous [[lidocaine]] solutions are often prescribed.<ref name="BoureauPelen1999" />
*Gargling with warm [[saline]] water.<ref name="urlTonsillitis - Treatment - NHS Choices">{{cite web |url=http://www.nhs.uk/Conditions/Tonsillitis/Pages/Treatment.aspx |title=Tonsillitis - Treatment - NHS Choices |format= |work= |accessdate=}}</ref>


==References==  
==References==  
{{Reflist|2}}
{{Reflist|2}}

Revision as of 21:00, 1 June 2017

Adenoiditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adenoiditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Medical Therapy

Antimicrobial therapy

  • If the adenoiditis is caused by group A streptococus, then antibiotics are useful with penicillin or amoxicillin being first line.[1]
  • Cephalosporins and macrolides are considered good alternatives to penicillin in the acute setting.[2]
  • Individuals who fail penicillin therapy may respond to treatment effective against beta-lactamase producing bacteria.[3] such as clindamycin or amoxicillin-clavulanate. Aerobic and anaerobic beta lactamase producing bacteria that reside in the adenoidal tissues can "shield" group A streptococcus from penicillins.[4]

Empiric Therapy

Challenges of Treatment

Despite in vitro efficacy, there is frequently reported inability of penicillin to fully resolve GABHS from patients with acute and relapsing adenoiditis.[6]

  • Over the past 50 years, the rate of penicillin failure has consistently increased from about 7% in 1950 to almost 40% in 2000.
  • There are several explanations for the failure of penicillin to eradicate GABHS adenoiditis:[7]
    • Poor penetration of penicillin into the adenoid tissues, as well as the epithelial cells.[8]
    • Bacterial interactions between GABHS and the other members of the adenoidal bacterial flora.[9]
      • It is hypothesized that the enzyme beta-lactamase, secreted by beta-lactamase-producing aerobic and anaerobic bacteria that colonize the pharynx, tonsils and adenoids, may “shield” GABHS from penicillin.
        • These organisms include S. aureus, Haemophillus influenzae, and Prevotella, Porphyromonas and Fusobacterium spp.[10] A recent increase was noted in the recovery of MRSA which was isolated from 16% of adenoids, making it more difficult to eradicate this and other beta-lactamase producing organisms.[11]
    • Coaggregation between Moraxella catarrhalis and GABHS, which can facilitate GABHS colonization.[12]
    • Absence of normal bacterial flora and resultant lack of interference on the growth of GABHS, makeing it easier for GABHS to colonize and invade the adenoid area.[13][14][15]
    • Poor penetration of penicillin into the adenoidal cells and adenoidal surface fluid (allowing intracellular survival of GABHS)[8]
    • Resistance (i.e., erythromycin) or tolerance (i.e., penicillin) to the administered antibiotic
    • Inappropriate dose, duration of therapy, or choice of antibiotic

Symptomatic Treatment and Pain Management

References

  1. Touw-Otten FW, Johansen KS (1992). "Diagnosis, antibiotic treatment and outcome of acute tonsillitis: report of a WHO Regional Office for Europe study in 17 European countries". Fam Pract. 9 (3): 255–62. doi:10.1093/fampra/9.3.255. PMID 1459378.
  2. Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 2004;113:866-882.
  3. Brook I (2009). "The role of beta-lactamase-producing-bacteria in mixed infections". BMC Infect Dis. 9: 202. doi:10.1186/1471-2334-9-202. PMC 2804585. PMID 20003454.
  4. Brook I (2007). "Microbiology and principles of antimicrobial therapy for head and neck infections". Infect Dis Clin North Am. 21 (2): 355–91. doi:10.1016/j.idc.2007.03.014. PMID 17561074.
  5. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
  6. Casey JR, Pichichero ME (2007). "The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis". Diagn. Microbiol. Infect. Dis. 57 (3 Suppl): 39S–45S. doi:10.1016/j.diagmicrobio.2006.12.020. PMID 17292576.
  7. Brook I, Foote PA (2005). "Efficacy of penicillin versus cefdinir in eradication of group A streptococci and tonsillar flora". Antimicrob. Agents Chemother. 49 (11): 4787–8. doi:10.1128/AAC.49.11.4787-4788.2005. PMC 1280135. PMID 16251332.
  8. 8.0 8.1 Kaplan EL, Chatwal GS, Rohde M. Reduced ability of penicillin to eradicate ingested Group A streptococci from epithelial cells: clinical and pathogenetic implications. Clin Infect Dis. 2006;43:1398-406.
  9. Brook I (1984). "The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection". Rev. Infect. Dis. 6 (5): 601–7. PMID 6390637.
  10. Brook I, Calhoun L, Yocum P (1980). "Beta-lactamase-producing isolates of Bacteroides species from children". Antimicrob. Agents Chemother. 18 (1): 164–6. PMC 283957. PMID 6968177.
  11. Brook I, Foote PA. Isolation of methicillin resistant Staphylococcus aureus from the surface and core of tonsils in children. Int J Pediatr Otorhinolaryngol. 2006 ;70:2099-102.
  12. Brook I, Gober AE (2006). "Increased recovery of Moraxella catarrhalis and Haemophilus influenzae in association with group A beta-haemolytic streptococci in healthy children and those with pharyngo-tonsillitis". J. Med. Microbiol. 55 (Pt 8): 989–92. doi:10.1099/jmm.0.46325-0. PMID 16849717.
  13. Grahn E, Holm SE (1983). "Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area". Zentralbl Bakteriol Mikrobiol Hyg A. 256 (1): 72–9. PMID 6362282.
  14. Brook I, Gober AE (1995). "Role of bacterial interference and beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococcal pharyngotonsillitis". Arch. Otolaryngol. Head Neck Surg. 121 (12): 1405–9. PMID 7488371.
  15. Brook I, Gober AE (1999). "Interference by aerobic and anaerobic bacteria in children with recurrent group A beta-hemolytic streptococcal tonsillitis". Arch. Otolaryngol. Head Neck Surg. 125 (5): 552–4. PMID 10326813.
  16. 16.0 16.1 16.2 Boureau, F; Pelen, F; Verriere, F; Paliwoda, A; Manfredi, R; Farhan, M; Wall, R (1999). "Evaluation of Ibuprofen vs Paracetamol Analgesic Activity Using a Sore Throat Pain Model". Clinical Drug Investigation. 17 (1): 1–8. doi:10.2165/00044011-199917010-00001. ISSN 1173-2563.
  17. "Tonsillitis - Treatment - NHS Choices".